» Articles » PMID: 38578378

A Comprehensive Investigation of the Interactions of Human Serum Albumin with Polymeric and Hybrid Nanoparticles

Overview
Publisher Springer
Specialty Pharmacology
Date 2024 Apr 5
PMID 38578378
Authors
Affiliations
Soon will be listed here.
Abstract

Nanoparticles (NPs) engineered as drug delivery systems continue to make breakthroughs as they offer numerous advantages over free therapeutics. However, the poor understanding of the interplay between the NPs and biomolecules, especially blood proteins, obstructs NP translation to clinics. Nano-bio interactions determine the NPs' in vivo fate, efficacy and immunotoxicity, potentially altering protein function. To fulfill the growing need to investigate nano-bio interactions, this study provides a systematic understanding of two key aspects: (i) protein corona (PC) formation and (ii) NP-induced modifications on protein's structure and stability. A methodology was developed by combining orthogonal techniques to analyze both quantitative and qualitative aspects of nano-bio interactions, using human serum albumin (HSA) as a model protein. Protein quantification via liquid chromatography-mass spectrometry, and capillary zone electrophoresis (CZE) clarified adsorbed protein quantity and stability. CZE further unveiled qualitative insights into HSA forms (native, glycated HSA and cysteinylated), while synchrotron radiation circular dichroism enabled analyzing HSA's secondary structure and thermal stability. Comparative investigations of NP cores (organic vs. hybrid), and shells (with or without polyethylene glycol (PEG)) revealed pivotal factors influencing nano-bio interactions. Polymeric NPs based on poly(lactic-co-glycolic acid) (PLGA) and hybrid NPs based on metal-organic frameworks (nanoMOFs) presented distinct HSA adsorption profiles. PLGA NPs had protein-repelling properties while inducing structural modifications on HSA. In contrast, HSA exhibited a high affinity for nanoMOFs forming a PC altering thereby the protein structure. A shielding effect was gained through PEGylation for both types of NPs, avoiding the PC formation as well as the alteration of unbound HSA structure.

Citing Articles

Core-Shell PLGA Nanoparticles: In Vitro Evaluation of System Integrity.

Kovshova T, Malinovskaya J, Kotova J, Gorshkova M, Vanchugova L, Osipova N Biomolecules. 2025; 14(12.

PMID: 39766308 PMC: 11674307. DOI: 10.3390/biom14121601.


Nose-to-Brain Delivery of Biomimetic Nanoparticles for Glioblastoma Targeted Therapy.

Ferreira N, Leite C, Moreno N, Miranda R, Pincela Lins P, Rodero C ACS Appl Mater Interfaces. 2024; 17(1):484-499.

PMID: 39692595 PMC: 11783514. DOI: 10.1021/acsami.4c16837.

References
1.
Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

2.
Ventola C . Progress in Nanomedicine: Approved and Investigational Nanodrugs. P T. 2017; 42(12):742-755. PMC: 5720487. View

3.
Kim H, Andrieux K, Delomenie C, Chacun H, Appel M, Desmaele D . Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis. 2007; 28(13):2252-61. DOI: 10.1002/elps.200600694. View

4.
Nakanishi K, Sakiyama T, Imamura K . On the adsorption of proteins on solid surfaces, a common but very complicated phenomenon. J Biosci Bioeng. 2005; 91(3):233-44. DOI: 10.1263/jbb.91.233. View

5.
Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson K . Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A. 2008; 105(38):14265-70. PMC: 2567179. DOI: 10.1073/pnas.0805135105. View